-
-
Comparing blood pressure medications, determining optimal length of androgen-deprivation therapy, red yeast rice for LDL reduction, and FDA Actions.
-
This issue is the second installment in a two-part series on breast cancer. The first part covered epidemiology, histologic types of breast cancer, screening, diagnosis, principles of treatment, and surgical management. This issue will cover chemotherapy, radiation therapy, endocrine therapy, metastatic breast cancer, and primary care for the breast cancer survivor.
-
The ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
-
The FDA has approved the first oral, selective vasopressin V2-receptor antagonist for the treatment of hypervolemic and euvolemic hyponatremia.
-
A polypill consisting of low doses of thiazide, atenolol, ramipril, simvastatin, and aspirin administered to 2053 subjects in 50 centers in India was effective in reducing multiple risk factors and cardiovascular risk.
-
A review of large randomized clinical trials for type 2 diabetes controlling HbA1c as low as 6.5-7.0% showed many consequences, but uncertain benefits. A new approach to type 2 diabetes should include individualized HbA1c targets along with cardiovascular risk reduction reflecting patients' values and preferences, and caution is urged in using these HbA1c values as performance measures to indicate inadequate care.
-
A higher intensity of comprehensive disease management for smoking cessation, similar to other chronic diseases, may yield superior results.
-
-
Clopidogrel and proton pump inhibitors; adverse events with tamsulosin after cataract surgery; new guidelines for persistent pain in the elderly; and FDA Actions.